Scientists mapped where drugs bind inside the body, cell by cell, to better understand benefits and side effects.

Researchers have found a new type of cross-link between amino acids in a protein (Nature 2021, DOI: 10.1038/s41586-021-03513-3). The intramolecular linkage is an N-O-S bridge formed by oxidizing the ...

Make room, disulfide crosslinks. There’s a new kind of crosslink in proteins. Instead of an S–S bridge connecting two cysteine residues, it consists of an N–O–S bridge between a lysine and a cysteine.

The newly launched Hyku Biosciences provides a platform for covalent drug development which may be a better approach for treating diseases like cancer. One of Hsu's SuTEx molecules targets sites on ...

“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that ...

Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases. Its founders include ...

Prior to 2000, many drugs that formed a covalent bond with targets did so non-selectively, which often led to undesired side effects when compared to non-covalent drugs. This led to the belief that ...

Firm led a $30 million financing and inked a $200 million option agreement for one preclinical program. Novartis Option Fund led a $30 million Series B financing round for Avila Therapeutics and ...